Welcome to our dedicated page for Kane Biotech news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on Kane Biotech stock.
Kane Biotech Inc. (KNBIF) is a leader in biofilm-disrupting technologies for advanced wound and scalp care. This page aggregates all official company announcements, providing stakeholders with timely updates on regulatory progress, product developments, and strategic initiatives.
Investors and industry professionals will find comprehensive coverage of FDA clearances, manufacturing partnerships, and global licensing agreements. Our curated news stream includes earnings reports, clinical advancements, and distribution expansions, ensuring you never miss critical developments affecting KNBIF's market position.
Key focus areas include updates about antimicrobial wound care solutions, scalp health innovations, and quality certifications like ISO 13485:2016. Bookmark this page for direct access to primary-source information about Kane Biotech's progress in combating biofilm-related health challenges worldwide.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced its second quarter 2024 financial results, highlighting a significant $10.4 million gain from the sale of STEM. Key financial highlights include:
- License and royalty income increased by 74% to $299,992
- Product and services revenue rose by 5% to $510,360
- Total revenue grew by 23% to $810,352
- Gross profit increased by 41% to $464,453
- Net income of $9,201,830 compared to a net loss of ($967,905) in Q2 2023
The company also reported several recent developments, including new distribution agreements, MDSAP Quality Certification, FDA removal of usage limitations on revyve™ Antimicrobial Wound Gel, and new funding from NRC IRAP for product development.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced the publication of a new review article on DispersinB® in the journal Pathogens. The article, authored by Dr. Jeffrey B. Kaplan, highlights the enzyme's broad-spectrum antibiofilm activity against over 25 bacterial species. Kane Biotech is also presenting research on its revyve™ Antimicrobial Wound Gel Spray at the Military Health System Research Symposium and the Symposium on Advance Wound Care. These presentations showcase the company's commitment to advancing biofilm science and developing potential treatments for chronic wound infections.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has signed a three-year distribution agreement with Qatar Datamation Systems (QDS) for its revyve™ Antimicrobial Wound Gel in the Qatar wound care market. This marks Kane's second distribution agreement in the Middle East and fourth overall for revyve™.
The company has previously secured distribution agreements for revyve™ in the United Arab Emirates, United States, Colombia, Costa Rica, and Panama. Kane Biotech also plans to commercialize revyve™ in Canada following its recent ISO 13485:2016 Medical Device Single Audit Program (MDSAP) certification.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced that it will release its second quarter 2024 financial results after market close on Thursday, August 29, 2024. Following the release, the company's management will host a conference call at 4:30 p.m. ET on the same day to review the financial results and discuss business developments during the period. Interested participants are required to register for the call using a provided link. It is recommended to join the call 10 minutes before the event, although pre-registration is available at any time. Additionally, a webcast of the call will be accessible on Kane Biotech's website in the Investor section at ir.kanebiotech.com.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has signed a three-year distribution agreement with Razan Medical & Surgical Equipment Trading for its revyve™ Antimicrobial Wound Gel in the United Arab Emirates (UAE) wound care market. This marks Kane's first distribution agreement in the Middle East and third overall for revyve™.
Hussain Malkawi, Managing Director of Razan Medical, expressed enthusiasm about introducing the product to benefit thousands of patients in the UAE. Kane's President & CEO, Marc Edwards, emphasized the company's commitment to commercialization and confidence in the partnership.
Kane has previously announced distribution agreements for revyve™ in the US, Colombia, Costa Rica, and Panama. The company also plans to commercialize the product in Canada following its recent ISO 13485:2016 Medical Device Single Audit Program (MDSAP) certification.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has secured up to $200,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to expand its revyve™ Antimicrobial Wound Gel product line. The funding, spread over 20 months, will support the development of three new products:
- revyve™ Antimicrobial Wound Gel Spray for sensitive wounds
- revyve™ Antimicrobial Wound Cleanser for various wound types
- Antimicrobial Surgical Gel for surgical/acute wounds
These extensions aim to provide higher price points or volumes, potentially scaling revenues rapidly. The company plans to leverage its expanded FDA 510(k) clearance for the revyve™ Antimicrobial Wound Gel in developing these new products.
Kane Biotech (TSX-V:KNE; OTCQB:KNBIF) has received FDA approval to increase the dosage allowance of its revyve™ Antimicrobial Wound Gel. The FDA has eliminated the previous 90 grams/month usage limitation, paving the way for the introduction of revyve™ Antimicrobial Wound Gel Spray. This new spray format is expected to be ideal for application on large wounds.
The removal of the usage restriction allows for increased use of the revyve™ product line in both prescription and over-the-counter (OTC) channels. This development is significant for Kane Biotech as it expands the potential market for their antimicrobial wound care products.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has achieved ISO 13485:2016 Medical Device Single Audit Program (MDSAP) Quality Certification as a designer, developer, and manufacturer of medical devices. This certification demonstrates Kane's commitment to quality products and allows the company to apply for regulatory approval of its revyve™ Antimicrobial Wound Gel in Canada, Australia, New Zealand, and Brazil.
The MDSAP certification enhances Kane's previous quality certification, which enabled FDA 510(k) clearance for revyve™. It signifies Kane's comprehensive quality management system focusing on patient safety, product performance, and reliability. This milestone brings Kane closer to improving the quality of products available for Canadian patients with chronic wounds and opens opportunities for expanding its product portfolio in these jurisdictions.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has issued 4,213,133 restricted share units (RSUs) to various directors, officers, employees, and consultants. These RSUs are part of the company's third amended and restated performance and restricted share unit plan, approved by shareholders on May 22, 2024. Each RSU can be exercised into one common share of the company, with vesting periods varying but not earlier than 12 months from the grant date. The PRSU Plan allows for a maximum of 25,177,198 RSUs, representing 19% of the company's issued and outstanding shares as of the shareholders' meeting date.
Kane Biotech has signed a worldwide licensing agreement with Omni Bioceutical Innovations for its coactiv+™ scalp care line. This five-year non-exclusive deal allows Omni to commercialize Kane's scalp detoxifier in the medical aesthetics market. Kane's products, launched in 2020 under the DermaKB™ brand, employ patented coactiv+™ technology to tackle issues like bacterial and fungal biofilms and shampoo residue buildup. Omni CEO Jane Christensen highlighted the product's efficacy and safety based on a large-scale consumer trial, predicting significant impact in the market. Kane CEO Marc Edwards expressed confidence in Omni's ability to globally market their innovative scalp care solutions.
FAQ
What is the current stock price of Kane Biotech (KNBIF)?
What is the market cap of Kane Biotech (KNBIF)?
